DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

Inclusion Criteria: * Age 18-75 years * BMI 27-40 kg/m2 * Stable bodyweight (\<5% reported change during the previous 3 months). * Diagnosed with T2DM \> 3 months prior to screening * Treatment with metformin and/or sulphonylurea at a stable dose for at least 3 months. * HbA1c 7.0-10% for patients treated with metformin * HbA1c 7.5-10% for patients treated with metformin and/ or sulphonylurea * For women: post menopausal (excluding possible menstruation cycle effects) Exclusion Criteria: * GLP-1 based therapies, DDP-4 inhibitors, SGLT-2 inhibitors, thiazolidinediones or insulin within 3 months before screening * Weight-lowering agents within 3 months before screening. * Congestive heart failure (NYHA II-IV) * Chronic renal failure (glomerular filtration rate \< 45 mL/min/1.73m2 per Modification of Diet in Renal Disease (MDRD)) * Liver disease * History of gastrointestinal disorders (including gastroparese, pancreatitis and cholelithiasis) * Patients with MEN2 syndrome or history or family history of medullary thyroid carcinoma * Neurological illness * Malignancy (except for basal cell carcinoma) * History of major heart disease * History of major renal disease * Pregnancy or breast feeding * Implantable devices * Substance abuse * Addiction * Alcohol abuse (defined as: for men \> 21 units/week, for women \>14 units/week) * Smoking/ nicotine abuse (defined as: daily smoking / a daily use of nicotine) * Contra-indication for MRI, such as claustrophobia or pacemaker * psychiatric illnesses; mood disorders, eating disorders, anxiety disorders, schizophrenia and other psychotic disorders, dissociative disorders, somatoform disorders, delirium, dementia and other cognitive disorders * Chronic use of centrally acting agents or glucocorticoids within 2 weeks immediately prior to screening * Use of cytostatic or immune modulatory agents * History of allergy for exenatide or other GLP-1 RA * Participation in other studies * Individuals who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry * Individuals who are investigator site personnel, directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. * Individuals who have previously completed or withdrawn from this study or any other study investigating GLP-1 receptor agonist or dipeptidyl peptidase (DPP)-4 within 6 months * Visual disability, not correctable with glasses or contact lens * Individuals who, in the opinion of the investigator, are unsuitable in any other way to participate in this study * Poor commandment of the Dutch language or any (mental) disorder that precludes full understanding the purpose, instruction and hence participation in the study * Further exclusion criteria will be in compliance with the EMeA SPC of exenatide and dapagliflozin